Tevogen highlights COVID-19 treatment data for immunocompromised patients

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) released clinical trial data for its investigational COVID-19 treatment TVGN 489, designed for individuals with weakened immune systems who face higher risks from SARS-CoV-2 infection.

The allogeneic immunotherapy uses Cytotoxic CD8+ T lymphocytes that target the entire viral genome rather than a single protein. Clinical trial results published in Blood Advances showed that treated patients received a single infusion of TVGN 489.

According to the data, viral elimination reached greater than 99% in all patients by day 14 in the treatment group. The trial included high-risk patients, with half being immunocompromised. Treated patients showed faster symptom resolution compared to the standard of care group, and no disease progression or Long COVID was observed in the treatment arm.

The treatment was well-tolerated across four dose levels and did not impair patients' natural immune responses. The therapeutic cells persisted in treated patients through six months of follow-up.

"An intact immune system is necessary to cure viral infections and TVGN 489 is designed to directly provide this immune help to individuals who need it," said Dr. Ryan Saadi, CEO of Tevogen Bio.

The company noted that TVGN 489 targets remain unaffected by mutations, including the current XFG SARS-CoV-2 variant. Dr. Neal Flomenberg, Chief Science Officer, stated that the XFG variant currently surging serves as a reminder that COVID-19 remains a year-round threat to vulnerable populations.

The information is based on a company press release statement.

You May Also Be Interested In